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Giuseppe Citerio, Nino Stocchetti, Diederik W J Dippel, Wilco C Peul
Health-care professionals and researchers have a legal and ethical responsibility to inform patients before carrying 
out diagnostic tests or treatment interventions as part of a clinical study. Interventional research in emergency 
situations can involve patients with some degree of acute cognitive impairment, as is regularly the case in traumatic 
brain injury and ischaemic stroke. These patients or their proxies are often unable to provide informed consent 
within narrow therapeutic time windows. International regulations and national laws are criticised for being 
inconclusive or restrictive in providing solutions. Currently accepted consent alternatives are deferred consent, 
exception from consent, or waiver of consent. However, these alternatives appear under-utilised despite being ethically 
permissible, socially acceptable, and regulatorily compliant. We anticipate that, when the requirements for medical 
urgency are properly balanced with legal and ethical conduct, the increased use of these alternatives has the potential 
to improve the efficiency and quality of future emergency interventional studies in patients with an inability to provide 
informed consent.
Introduction 
Health-care professionals and researchers have the 
legal and ethical responsibility to inform patients before 
executing procedures as part of a clinical study.1,2 Each 
patient has the right to refuse study participation.2 This 
right is internationally recognised and formalised in 
many declara tions, regulations, directives, and laws.1–4 For 
research involving humans, physicians must consider the 
appli cable international norms and standards, as well 
as their country’s general ethical, legal, and regulatory 
standards.2 From a legal perspective, obtaining informed 
consent is focused on liability and establishing a shared 
responsibility between professionals and patients, while 
from a moral perspective, the focus is mostly on respecting 
autonomous choices and actions of the patient. The pro-
cess of informed consent is a multidimensional process 
that serves several important ethical functions.5–7
Obtaining informed consent is especially challenging 
in patients with acute medical emergencies with com-
promised decision-making capacity from traumatic brain 
injury and ischaemic stroke because: (1) the short thera-
peutic time window necessitates urgent intervention 
without unnecessary delay, (2) the acute or life-threatening 
condition associated with acute cognitive impairment 
impedes obtaining valid patient informed consent before 
intervention, and (3) obtaining consent before inter-
vention from proxies is not always possible, because they 
cannot always be located or contacted within the time 
window or they are unable to provide consent for other 
reasons. These difficulties are probably contributing to the 
international variation in policy and practice regarding 
consent procedures for emergency research.8–11
Investigating novel, potentially effective therapeutic 
options for these patients is essential because traumatic 
brain injury and ischaemic stroke are associated with high 
rates of mortality and morbidity, which is a major burden 
for patients, proxies, and societies.12,13 Moreover, many 
available treatments are still largely unproven or of little 
benefit.12–15 To facilitate research to improve health and 
functional outcome in these patients, sev eral pragmatic 
solutions are used to overcome the inability of obtaining 
patient informed consent before urgent medical inter-
vention. However, the legal basis for these solutions is not 
universally present.
In this Personal View, we outline the theoretical and 
ethical basis of four different informed consent procedures 
in emergency interventional research and their use and 
challenges in common practice, focussing on patients 
with traumatic brain injury and ischaemic stroke with an 
inability to provide consent. We also provide procedu-
ral recommendations for future emergency research 
initiatives.
Patient informed consent before medical intervention 
Patient informed consent before medical intervention is 
an ethical cornerstone of research involving humans, but 
obtaining valid patient informed consent before medical 
intervention for emergency interventional research in 
traumatic brain injury or ischaemic stroke is challenging. 
Most patients with severe acute injury from traumatic 
brain injury or ischaemic stroke have neurological 
defi cits that limit their ability to make or communi-
cate autonomous decisions about research participation. 
The inability to provide consent is usually caused by a 
decreased level of consciousness, cognitive impairments, 
or pharmacological sedation.12,13 In patients who are less 
severely injured, and with variable clinical presentation, 
this inability can also be difficult to establish.12,13 Problems 
with obtaining consent are frequently caused by factors 
like cognitive impairment or aphasia.16,17 The latter is 
present in up to 45% of patients in acute stroke trials, of 
which 30% have severe aphasia.18 Variability between 
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injuries, and especially injury severity, has implications 
for how consent might need to be approached. To avert 
consent problems, researchers have adjusted study proto-
cols by excluding patients with aphasia, left-hemisphere 
stroke, and moderate or severe cognitive impairment. 
This approach could, however, cause selection bias and 
limit external validity of study results.10,19–22
Several measures of capacity have been proposed to 
provide more accurate measurement of decisional capacity, 
but all have substantial limitations. 7,23 We propose several 
conditions that could be used to help determine the validity 
of patient consent before intervention (panel 1). When 
determining consent validity, researchers must balance 
between two undesirable extremes: (1) having a low 
threshold for inclusion and a risk of including patients 
who might not understand what they are agreeing to, and 
(2) having a high threshold for inclusion and including 
patients without trying to get their consent at all.
In the context of emergency interventional research in 
traumatic brain injury and ischaemic stroke, time con-
straints make it impossible to await recovery to provide 
valid patient consent before intervention. Although con-
sent is often obtained in parallel with imaging, laboratory 
tests, or readying an angiographic suite or operating 
theatre, obtaining patient consent before intervention 
could further delay treatment. This approach is proble-
matic because study interventions might need to be 
delivered in a very short therapeutic time window to 
be effective.24,25 Secondary brain injury after traumatic brain 
injury can be less severe when treatment is initiated early26 
and stroke outcomes are better when reperfusion therapy 
is administered at the earliest opportunity.27,28 A delay of 
1 h in reperfusion time in patients with ischaemic stroke is 
associated with an increase of absolute risk of 6·0–7·7% 
for unfavourable functional outcome (modified Rankin 
Scale score 0–2).29,30 The ULTRA-study31 included patients 
with decisional capacity without patient consent before 
intervention because delay in ultra-early administration of 
the study intervention could compromise its potential 
effect, and thereby invalidate trial design and trial outcome. 
Obtaining consent was even considered unethical because 
patients would have been exposed to unnecessary risk.31 
Several options to minimise time-to-consent have been 
suggested, ranging from information leaflets to the use of 
electronic consenting by telemedicine or smartphones.32–34 
Nonetheless, many studies have described recruitment 
problems related to informed consent procedures.21,26,35 
These problems are not limited to patients in acute care 
settings, but also occur when patients are exposed to 
continued and pro longed study activities.
To determine the approaches to informed consent 
procedures used by traumatic brain injury and ischaemic 
stroke researchers, we examined a representative sample 
of randomised controlled trials in emergency traumatic 
brain injury (n=70) and ischaemic stroke (N=76) literature 
(appendix pp 3–16; panel 2). Type of consent was reported 
in 61 (87%) of 70 randomised controlled trials on traumatic 
brain injury and in 71 (93%) of 76 randomised controlled 
trials on ischaemic stroke. Patient consent before medical 
intervention was mentioned to be the only consent option 
in 3 (5%) of 61 randomised controlled trials on traumatic 
brain injury and five (7%) of 71 randomised controlled 
trials on ischaemic stroke. In total, patient consent before 
inter vention was reported to be an option in 15 (25%) of 
61 randomised controlled trials on trau matic brain injury 
and 68 (96%) of 71 randomised controlled trials on ischae-
mic stroke (table; panel 3). Obtaining patient consent 
before intervention was often stated to be impossible 
because of the sustained brain injury (appendix pp 3, 
16–17). In these cases, researchers resorted to three alterna-
tives to patient informed consent before inter vention, 
proxy informed consent before intervention, deferred 
consent, and excep tion from informed consent or waiver 
of consent.
Proxy informed consent before intervention 
Proxy informed consent before intervention was the most 
commonly used alternative for patient consent before 
intervention and used in most randomised controlled 
trials on traumatic brain injury (56 [92%] of 61) and 
ischaemic stroke (63 [89%] of 71;  table). Proxy informed 
consent before intervention is provided by an individual 
Panel 1: Prerequisites for obtaining valid patient or proxy 
informed consent before intervention
Disclosure
The patient or proxy should be provided with complete and 
understandable information about the purpose, duration, 
potential risks or benefits, and possible other consequences 
of the study.
Understanding
The patient or proxy should fully understand all provided 
information.
Authenticity
The patient or proxy can make a judgement, which is 
consistent with the patient’s personal values.
Non-control
The patient or proxy should be able to make a decision 
without coercion, manipulation, or other undue influences.
Capacity
The patient or proxy should be able to oversee the 
consequences of providing informed consent and thereby 
study participation.
Intentionality
The patient or proxy should have the intention to participate 
in the study.
Time
The patient or proxy should be provided sufficient time to 
decide on informed consent for study participation.
See Online for appendix
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who has the legal right to provide consent on behalf of 
the patient. There are many descriptions in the litera-
ture because the legal base that regulates the selection of 
individuals to act as proxy is variable: consent by a 
family member, a relative, an appointed person or legally 
authorised representative; surrogate or substitute decis ion 
maker; guardian permission; and sometimes inde pendent 
physician consent. Independent physicians could serve as 
proxies for informed consent decisions in two (3%) of 
61 randomised controlled trials on traumatic brain injury 
and in two (3%) of 71 trials on ischaemic stroke. The 
conditions listed in panel 1 could also be considered to 
assess validity of proxy informed consent before inter-
vention. Examples of where proxy informed consent 
before intervention is approved include the Australia, 
Ethiopia, European Union, Chile, China, India, Japan, 
North America, South Africa, and New Zealand, and is 
described as valid in the Declaration of Helsinki2 and the 
International Ethical Guidelines for Health-related 
Research Involving Humans (appendix p 21).4
The two main barriers to obtain proxy informed consent 
before intervention in emergency research are the short 
therapeutic time window that precludes a consent con-
versation, and the fact that proxies cannot always be 
located or contacted. 21,35,36 As with patient consent before 
intervention, delaying a timely start of study interventions 
to obtain proxy informed consent before intervention is 
undesirable as it can decrease the efficacy of the acute 
therapy.26–28
A third barrier is that proxy decision making in research 
is highly complex and, although proxies prefer to be 
involved, empirical evidence suggests that proxies might 
not always be suitable as surrogate decision makers.37,38 
Substantial discrepancies are described between decisions 
of patients and proxies in hypothetical scenarios.39,40 About 
50% of proxies reported to be comfortable with being 
involved, but many are also emotionally overwhelmed, 
stressed, dis tracted, or report symptoms of anxiety and 
depression.37,41–43
Proxies aim to make a decision that is authentic to 
the person they represent by balancing factors such as 
patients values, preferences, and wellbeing.38,44–47 Other 
factors that affected decisions include the time sensitivity 
of the decision, perceived study risk or benefit, uncertainty 
of possible outcomes, the complexity of the patient’s 
condition, the use of medical terminology, and com muni-
ca tion with physicians and nurses.37,47,48 Study par ticipation 
is often declined because proxies feel unable or unwilling to 
consider it.49,50 Other common reasons to decline con-
sent were being too anxious (67%), fear of experi mental 
treatment (37%), and concerns about risks (33%).44 Reasons 
to provide consent were wanting to help others (91%), 
contributing to medical progress (88%), and trusting (87%) 
or not wanting to disappoint the medical team (10%).44
In summary, alternatives to patient or proxy informed 
consent before intervention are sometimes needed in 
traumatic brain injury or ischaemic stroke emergency 
interventional research because of the short thera-
peutic time windows, the deficits caused by traumatic 
brain injury or ischaemic stroke, and the frequent lack 
of avail able proxies. All factors preclude determining 
a patient’s preferences. When patient or proxy informed 
con sent before inter vention are not practicable, the use of 
consent alternatives is imperative.51
Deferred consent 
This procedure allows participants to be included in 
studies when patients and proxies are unable to provide 
valid previous consent within short time frames. The 
approach was infrequently reported as an option in our 
analysed sample of randomised controlled trials on 
traumatic brain injury (eight [13%] of 61) and ischaemic 
stroke (three [4%] of 71), nearly always in addition to patient 
and proxy informed consent before intervention (table). It 
is usually described as deferred patient or proxy consent, 
retrospective consent, delayed consent, implied consent 
and consent to continue, or recon sent from patient, and is 
Panel 2: Search strategy and selection criteria
We searched PubMed and Ovid MEDLINE using several 
strategies. To be informed about the used consent 
procedures in current traumatic brain injury and ischaemic 
stroke emergency research practice, we used a representative 
selection of randomised controlled trials. Data on study 
design and used consent procedures were extracted. Details 
on the search strategies, article selection procedures, data 
extraction, and synthesis of results can be found in the 
appendix p 3–17. We found articles on the theoretical and 
conceptual aspects of consent procedures specifically for 
patients with traumatic brain injury and stroke using search 
terms, including ‘informed consent’, ‘brain injuries’, ‘head 
injuries’, and ‘stroke’ (appendix p 18). We focussed on 
theoretical and conceptual articles about the most 
commonly used consent procedures (appendix p 20). 






Type of consent reported 61 (87%) 71 (93%)
Patient informed consent before 
medical intervention
15 (25%) 68 (96%)
Proxy informed consent before 
intervention
56 (92%) 63 (89%)
Deferred consent 8 (13%) 3 (4%)
Exception from informed consent 
waiver of informed consent
6 (10%) 5 (7%)
Physician consent or other 
consent type
2 (3%) 2 (3%)
Data are n (%).
Table: Consent procedures used in randomised controlled trials on 
traumatic brain injury and ischaemic stroke
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allowed and practised in places such as the Australia, 
European Union, China, India, Japan, and South Africa. It 
is described as valid in the Declaration of Helsinki2 and in 
the International Ethical Guidelines for Health-related 
Research Involving Humans.4 After starting study pro-
cedures without patient informed consent before inter ven-
tion or proxy informed consent before inter vention, 
consent must be obtained for study continuation as soon 
as patients or proxies regain the ability to provide consent. 
Some authors recommend a time limit of 72 h to prevent 
unauthorised use of conducting research without previous 
consent,41 but there is no legal or moral ground for this 
recommendation.52 When it remains impossible to get 
affirmative consent for study continuation for reasons 
other than death, it could be necessary to withdraw patients 
from the study. This depends on the specific study 
circumstances and pro cedures as reviewed and approved 
by a responsible institu tional review board. When consent 
for study continuation is provided, already collected data 
can be used. When study continuation is refused, already 
collected data can still be used when patients or proxies do 
not use their right to refuse this.
The procedural particulars depend on local legisla tion, 
institutional review board requirements, and their assess-
ment of the relative pros and cons. Respecting local 
requirements is important, but also has a risk of practice 
variation and use of different terms or descriptions, both 
resulting in indistinctness, misunderstanding, and even 
misuse.8–10 Researchers should be aware of this possibility 
and multi national studies therefore need to be flexible 
enough to tailor their approach to all applicable require-
ments.53 Although most researchers use the deferred 
consent pro cedure to obtain consent for study continua-
tion, it is some times interpreted as a requirement to obtain 
consent for research activities that have already taken 
place. However, considering the earlier suggested con-
ditions (panel 1) and the actual meaning of consent (give 
permis sion for something to happen or agreement to do 
some thing), it can only be concluded that asking and 
obtaining valid consent is possible only for research 
activities in the future.
Many patients and proxies report to be willing to 
participate in a study without previous consent.42,50,54,55 
Although the deferred consent procedure was not always 
supported afterwards,56 most proxies of patients included 
in acute care studies (81–100%) without previous informed 
consent agreed to further participation.49,56–58 Only few 
patients that refused further participation also denied 
permission for the use of already collected data.58 Experi-
enced stress in the setting of an intensive care unit 
admission was commonly mentioned as reason to endorse 
the use of a deferred consent procedure.42
A deferred consent procedure is also being used in 
three ongoing randomised controlled trials on modifi-
cations of endovascular treatment for acute ischae-
mic stroke (MR CLEAN-MED, MR CLEAN-NO IV, MR 
CLEAN LATE) within the CONTRAST consortium.59 On 
Nov 8, 2019, preliminary data were available for 742 patients 
of these CONTRAST studies, of whom 664 (90%) patients 
or proxies provided written consent after the trial treat-
ment, and 36 (5%) patients died before consent could be 
obtained. Written consent for study continuation was not 
obtained in 42 patients (6%), of whom half did not object 
to the use of already collected data. The observation, that 
postponing consent until after the study treatment is 
usually accepted by patients and proxies, has been shown 
in previous (non-stroke) clinical studies.43,55
In the CONTRAST studies, the median time from 
admission at the intervention centre to randomisation was 
25 min (IQR 16–39), which was shorter than the earlier 
MR CLEAN trial (76 min; IQR 48–144).60 In the MR CLEAN 
trial,60 which compared endovascular treatment with usual 
care versus usual care alone, written patient or proxy 
informed consent before intervention was obtained based 
on oral communication and an abbreviated infor mation 
letter.60 Written consent was asked again after the acute 
phase. Although workflow has improved substantially over 
time, the difference between these time intervals could 
suggest that valuable time is lost when using patient 
consent or proxy informed consent before intervention. 
This additional time can delay intervention, which could 
negatively affect effectiveness of the acute intervention.29,30
Panel 3: Comparison of consent procedures in traumatic brain injury and ischaemic 
stroke literature
There are similarities and differences between the types of consent reported in traumatic 
brain injury and ischaemic stroke literature (appendix p 16). First, the patient consent before 
intervention option was reported to be used less frequently in randomised controlled trials 
on traumatic brain injury (25%) than in randomised controlled trials on ischaemic stroke 
(96%; table). This difference does not necessarily mean that patient consent before 
intervention was impermissible when a participants’ consent capacity was intact, but could 
also mean that it was not considered applicable or relevant for the study population. The 
difference likely depends on patient and study characteristics and is probably related to a 
perceived continued ability to provide patient informed consent before intervention after 
ischaemic stroke in most patients, whereas traumatic brain injury generally has a greater 
effect on this ability. This might be especially true in the case of more severe traumatic brain 
injury, additional extracranial injury, and a need for intensive care unit admission.
Second, the reported possibility to use proxy informed consent before intervention was 
very high in both literature on traumatic brain injury (92%) and ischaemic stroke (88%), 
and the use of independent physician consent procedures was equally low (3·3% vs 2·8%). 
Third, the use of deferred consent and exception from consent was higher in randomised 
controlled trials on traumatic brain injury (23%) than in those on ischaemic stroke (11%), 
probably for the same reasons as reported for patient informed consent before 
intervention differences. There seems to be an increase in randomised controlled trials 
allowing patient recruitment without patient informed consent before intervention or 
proxy informed consent before intervention; however, many studies did not use it as an 
alternative for patient informed consent or proxy informed consent before intervention.
Last, there were more missing descriptions of consent procedures in the literature on 
traumatic brain injury (13%) than on ischaemic stroke (6·6%), which is likely caused by the 
inclusion of more dated randomised controlled trials on traumatic brain injury. Nearly all 
newer studies included a description of informed consent procedures.
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Emergency research in acute traumatic brain injury and 
ischaemic stroke often includes patients who die after 
being included without patient or proxy informed consent 
before intervention. Exclusion of included patients who 
have died before consent was obtained is obviously 
undesirable, as it reduces statistical power, introduces 
selection bias, causes asymmetrical randomisation, and 
decreases external validity.41,61 When privacy is guaranteed, 
using already collected data is judged to be ethically 
valid.41,61 Explicit proxy consent is not required in these 
circumstances. Retrospective removal of study patients 
from a database, after randomisation, for any reason, not 
just death, is even considered to be a threat to the scientific 
integrity of the trial. Scientific integrity is necessary for any 
trial to be ethically justifiable.
Exception from consent 
Exception from consent was used in six (10%) of 
61 randomised controlled trials on traumatic brain injury 
and in five (7%) of 71 on ischaemic stroke and is also called 
waiver of informed consent. By contrast to the deferred 
consent procedure, patient or proxy informed consent are 
not required for continuation of study-related activities if 
the patient or a proxy never becomes available to engage 
in an informed consent pro cess, despite diligent good-
faith efforts by the researchers. It is particularly practiced 
in North America and Ethiopia, and described as valid in 
the Declaration of Helsinki2 and in the International 
Ethical Guidelines for Health-related Research Involving 
Humans.4 In an effort to improve the progress in emer-
gency research involving patients unable to provide 
informed consent, the US American Food and Drugs 
Administration (FDA) published guidelines in 1996, 
describ ing the excep tion from informed consent require-
ments for emergency research and the waiver of informed 
consent (appendix p 21). Since the guidelines, exception 
from informed consent has been available for use in 
emergency research for US FDA regulated products and 
waiver of informed consent for non-FDA regulated 
products.
With this alternative, a study can start without patient or 
proxy informed consent before intervention. Relevant 
information on study participation and use of data should 
be communicated to patients or proxies at the earliest 
opportunity. Refusal of study continuation or use of already 
obtained data should always be respected. The exception 
from informed consent procedure could be necessary 
when patients are exposed to continued and prolonged 
study activities while obtaining patient or proxy informed 
consent before intervention is not possible. The participant 
remains in the study by default.
Community consultation or public disclosure are 
specifically required to support the use of exception from 
informed consent or waiver of informed consent and aim 
to protect the rights and welfare of study participants.62 
In community consultation, representatives from gen-
eral communities (geographic community) or from the 
popula tion at risk for the condition (condition-oriented 
com munity) are recruited. It aims to involve and engage 
community members with research initiatives by using 
public fora, community groups, or face-to-face and tele-
phone surveys. Public disclosure involves notifying the 
community in advance that patients will be enrolled in a 
study in an emergency situation without patient or proxy 
informed consent before intervention. After the study, 
results will be communicated to participants and the 
public. It remains unclear whether patients, proxies, 
health-care providers, administrators, or a general popula-
tion should be con sidered to be the community.63 Although 
some reports are positive and participants satisfied,64,65 
community consultation and public disclosure are also 
challenging, time consuming, and costly.66,67
A study68 reviewed 28 completed and published acute 
care studies between 1996 and 2018, that used exception 
from informed consent or waiver of informed consent.68 
Only 359 (0·6%) of 63 947 study enrolments were with-
drawn or did not provide consent for continued study 
participation.68 Acceptance of the exception from informed 
consent procedure was high and varied by the specifics of 
the situation.65,69
Implications for research practice 
The difficulties regarding patient and proxy informed 
consent before study intervention in traumatic brain 
injury and ischaemic stroke emergency interventional 
research can result in many lost research opportunities 
when alternatives for informed consent are not facilitated.43 
Based on the sample of randomised controlled trials, 
patient recruitment without patient and proxy informed 
consent before study intervention seems to be increas-
ingly used in recent years, but still many studies do not 
use it. The use and efficiency of consent procedures in 
traumatic brain injury and ischaemic stroke emergency 
research should be improved.
Selecting an appropriate informed consent procedure 
for a study is difficult and depends on many factors, often 
related to each other. Factors include local legislation, 
institutional review board requirements, and study details 
such as methods, interventions, and patient characteristics. 
We propose use of a flow chart to guide investigators or 
regulators to select the most appropriate informed consent 
procedures based on several study particulars (figure). 
Informed consent procedures should be used as over-
lapping and complementary strategies to solve different 
challenges of a study. Researchers should first determine 
whether the therapeutic time window allows time for an 
informed consent procedure. If there is time, it should 
also be determined whether it is feasible to obtain valid 
patient or proxy informed consent before intervention 
within the time window. The conditions suggested in 
panel 1 could be used as a starting point to assess consent 
validity. If both are not practicable, the determination of a 
patient’s wishes regarding study participation should be 
considered not possible. Researchers should then consider 
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the option of using an alternative procedure like deferred 
consent or exception from informed consent or waiver of 
informed consent. This choice mainly depends on local 
legislation and study details. A non-exclusive list of 
prerequisites of both procedures, based on existing 
legislation, as listed in appendix p 21, can be found in 
panel 4. These prerequisites are not intended to be con-
clusive, but could assist researchers in determining the 
appropriateness of the procedure. All procedural decisions 
should adhere to applicable legislation.
The use of deferred consent or exception from informed 
consent or waiver of informed consent proce dures seems 
necessary and acceptable in traumatic brain injury and 
ischaemic stroke emergency inter ventional research. The 
seriousness of the potential threats to the welfare and 
protection of study participants, the scientific integrity of 
a trial, and public trust in research should however never 
be under estimated.70,71 Independent institutional review 
boards or steering committees are charged with the protec-
tion of patients, researchers, and the public as a whole, by 
Figure: Flow chart for the selection of appropriate informed consent procedures in emergency interventional research
Proposed flowchart to guide investigators or regulators to select the most appropriate informed consent procedure based on several traumatic brain injury or ischaemic stroke study particulars. Studies 
could use multiple informed consent procedures in their informed consent strategy. Informed consent procedures should be used as overlapping and complementary strategies to solve different 
challenges of a study. This flowchart could be best seen as a legal and ethical framework that could be considered in any research setting. It is not binding, and a chosen informed consent strategy should 
always follow applicable legislation and must be evaluated and approved by the responsible institutional review boards. *Some emergency interventional studies on traumatic brain injury and ischaemic 
stroke use a very narrow therapeutic time window (ie, mins) that does not allow any time for an informed consent procedure. Obtaining patient or proxy informed consent before intervention is not 
possible in these situations, because the intervention is immediate. Obtaining informed consent can delay the study intervention. In some studies, any delay of study intervention is problematic because 
it could compromise the potential effect of the experimental treatment,making the fair interpretation of results difficult. Obtaining informed consent and delaying the study intervention could also be 
considered unethical because patients would be exposed to unnecessary risk. In other studies, where the therapeutic time window of traumatic brain injury or ischaemic stroke intervention is wider 
(ie, several hrs), there might be an opportunity to obtain patient or proxy informed consent. †There are many reasons why it could not be possible to obtain patient or proxy informed consent before 
intervention even when this could have been possible within the therapeutic time window. Reasons include an absence of available proxies, and a patient’s or proxy’s inability to provide informed 
consent. ‡Strategies to optimise and support patient or proxy decision making could help to optimise informed consent procedures. §The use of deferred consent or exception from consent or waiver of 
consent procedures depends on study particulars and local legal frameworks, including requirements from institutional review boards. Details can be found in the main text of the manuscript and cited 
references. Their use should be carefully considered and evaluated by researchers and institutional review boards. ¶Informed consent to continue study-related activities should be obtained as soon as 
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balancing and judging their inter ests. Several safe guards 
are used in the process: a rigorous evaluation of study 
protocols, oversight in study pro cedures such as patient 
screening, recruitment, consent procedure, and indepen-
dent safety monitoring.7 Other safeguards could consist of 
includ ing and consulting more repre sentatives of patients 
on institutional review boards to weigh in on the ethics 
of different trial approaches in patients where patient or 
proxy informed consent before intervention is not possible.
Conclusions and future directions 
There is an urgent need to investigate novel therapeutic 
options that are potentially effective for patients with 
traumatic brain injury and ischaemic stroke. A thorough 
consideration of the multidimensional process of informed 
consent is required to increase the feasibility and quality of 
future emergency research initiatives. Researchers should 
be aware of the international legal and ethical conditions 
and possibilities. Implementing this knowledge could 
improve study protocol and procedures.
Supported by an extensive literature base, we conclude 
that obtaining patient or proxy informed consent before 
inter vention is often not possible in emergency interven-
tional research in patients with traumatic brain injury or 
ischaemic stroke. This impossibility is primarily caused 
by the impor tance of very narrow therapeutic windows, 
the inability to provide informed consent, or the frequent 
absence of surrogate decision makers.
Generally accepted alternatives, such as deferred con-
sent and exception from informed consent or waiver of 
Panel 4: A list of prerequisites for the use of deferred consent and exception from consent procedures
General prerequisites for the use of deferred consent and 
exception from consent procedures
1 The patient has an acute life-threatening situation or an 
acute medical condition that necessitates urgent (study) 
procedures because delayed treatment can negatively affect 
intervention effectiveness or patient outcome. Due to the 
urgency of the situation, the patient or proxies are unable to 
provide valid informed consent before intervention.
2 The medical condition causes an inability to provide 
informed consent before intervention by patient or proxy.
3 There is scientific information that supports the potential 
for the study treatment to provide a direct benefit to the 
patient. Available standard treatments are unproven 
(the scarcity of high-quality evidence that the treatment is 
effective) or unsatisfactory (the treatment is unsatisfactory 
due to safety or efficacy issues that require investigation).
4 The risks and burden of study participation are considered 
acceptable compared with standard treatment, given the 
potential direct benefit of the study treatment.
5 Researchers or physicians are unaware of any objections for 
study participation (eg, a written advanced directive).
6 It is reasonably impossible to prospectively identify 
individuals that are likely to become eligible for study 
participation in the future, in such a way that patient or 
proxy informed consent before intervention could 
be obtained.
7 It is practically impossible to undertake the emergency 
research when patient or proxy informed consent before 
intervention is required to start study-related activities.
8 A comprehensive disclosure of study information and study 
participation to patients and proxies is required at the 
earliest possible (practicable) opportunity.
9 If the patient dies during the study before informed consent 
has been obtained, the already collected data can be used 
according to the study protocol, without the need for proxy 
informed consent. Proxies should be informed about study 
participation at the earliest possible (practicable) 
opportunity.
10 The use of this alternative for patient or proxy informed 
consent before intervention is accepted by local legislation. 
Institutional review boards have reviewed and approved 
the study protocol to prevent misconduct and ascertain 
patient safety.
Specific prerequisites for deferred consent
1 It is considered possible to continue essential study-related 
activities, such as additional interventions or follow-up, 
when patient or proxy informed consent is required to 
continue study-related activities. For example, patients or 
proxies are not expected to have a prolonged inability to 
provide valid informed consent.
2 Patient or proxy informed consent is required for 
continuation of study-related activities and should be 
obtained from the patient or proxy at the earliest possible 
(practicable) opportunity after regaining the ability to 
provide informed consent. When study continuation is 
refused, the patient or proxy has the right to refuse the use 
of already obtained data.
3 There are no pre-study requirements such as community 
consultation or public disclosure.
Specific prerequisites for exception from consent
1 It is practically impossible to continue essential study-
related activities, such as additional interventions or follow-
up, when patient or proxy informed consent is required to 
continue study-related activities. For example, patients or 
proxies are expected to have a prolonged inability to 
provide valid informed consent.
2 Written patient or proxy informed consent is not required 
for continuation of study-related activities if the patient or a 
proxy never becomes available to engage in an informed 
consent process despite diligent good-faith efforts by the 
researchers. Patients or proxies should be informed about 
their right to refuse the use of obtained data.
3 To increase acceptance of the proposed study protocol, 
pre-study requirements such as community consultation or 
public disclosure could be required.
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informed consent, appear underutilised in traumatic brain 
injury and ischaemic stroke emergency inter ven tional 
research, despite being ethically permissible, socially 
acceptable, and regulatorily compliant. Not being able to 
use these alternatives complicates emergency interven-
tional research in these patients. Being able to use them, 
when appropriate, has the potential to optimally test 
interventions earlier in a patient’s course when they are 
most likely to be effective. If done properly, it also creates 
an opportunity for more generalisable and equitable 
clinical trial participation and results. Using these alterna-
tives appears consistent with the desires of most patients 
most of the time.
Institutional review boards have an important role to 
prevent misconduct and protect patient safety by reviewing 
and approving study protocols. Study procedures should 
be overseen during the study. Researchers should aim to 
optimise the use of overlapping and complementary 
informed consent strategies based on the particular 
circum stances of a study, especially the requirements and 
constraints on obtaining patient or proxy informed 
consent before intervention. Harmonisation of laws and 
regulations between countries should be pursued, while 
respecting national sovereignty and local cultural prefer-
ences. All measures will further improve the efficiency 
and quality of emergency research initiatives involving 
patients with an inability to provide informed consent 
before medical intervention, regardless of disease.
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